AstraZeneca and AVANIR Announce Global Alliance to Discover and Develop Novel Reverse Cholesterol Transport Enhancing Compounds.
Linked as:
Extract
AstraZeneca and AVANIR Announce Global Alliance to Discover and Develop Novel Reverse Cholesterol Transport Enhancing Compounds.
LONDON & SAN DIEGO -- AstraZeneca PLC today announced an exclusive global licensing and research collaboration agreement with AVANIR Pharmaceuticals (AMEX:AVN) to discover, develop and commercialise Reverse Cholesterol Transport (RCT) enhancing compounds for the treatment of cardiovascular disease.
RCT enhancing...See the full content of this document
Sponsored links
